SLC5A2 and hydrops fetalis: For example, the use of dapagliflozin over 12 weeks compared to placebo in the DEFINE-HF clinical trial showed an increase in the levels of peripheral metabolites enriched with ketone bodies, as well as short- and medium-chain acylcarnitines, potentially indicating some degree of metabolic reprogramming during SGLT2 inhibitor therapy44.